1,310 results match your criteria Immunotherapy [Journal]


Clinical value of neutrophil-to-lymphocyte ratio as a predictor of prognosis of RetroNectin-activated cytokine-induced killer cell therapy in advanced non-small-cell lung cancer.

Immunotherapy 2018 Dec 14. Epub 2018 Dec 14.

Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, PR China.

Aim: To assess the impact of neutrophil-to-lymphocyte ratio (NLR) on time to progression (TTP) and overall survival (OS) and explore the value of NLR as an indicator in patients with non-small-cell lung cancer (NSCLC) treated with RetroNectin-activated cytokine-induced killer (R-CIK) cells.

Patients & Methods: Using data gathered from a single center between January 2010 and June 2015, 201 patients with stage IIIB or IV NSCLC receiving at least four cycles of R-CIK cell therapy were included. Univariate and multivariate Cox regression analyses were performed to evaluate the associations of NLR with TTP and OS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0147DOI Listing
December 2018

α-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8 T-cell infiltration.

Immunotherapy 2018 Dec 4. Epub 2018 Dec 4.

Department of Radiation & Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China.

Aim: We investigated a promising cooperative combination of radiotherapy (RT) and programmed death ligand 1 (PD-L1) monoclonal antibodies (mAb) in both local and abscopal tumors.

Materials & Methods: C57BL/6 mice were randomly grouped and received RT, α-PD-L1 mAb or combination therapy 13 days after implantation of Lewis lung carcinoma cells. Flow cytometry and immunohistochemistry analyses demonstrated CD8 T-cell infiltration and PD-L1 expression in tumor issue. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0049
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0049DOI Listing
December 2018
8 Reads

A study of the clinical characteristics and prognosis of advanced mucosal and cutaneous melanoma in a Chinese population.

Immunotherapy 2018 Dec 4. Epub 2018 Dec 4.

Department of Biotherapy, Affiliated Cancer Hospital of Zhengzhou University, 127 Dong Ming Road, Jinshui District, Zhengzhou, Henan, 450008, PR China.

Aim: To investigate the characteristics and prognosis of melanoma in a Chinese population.

Materials & Methods:  Total of 162 advanced melanoma patients were analyzed retrospectively. Kaplan-Meier method and Log rank test were used for survival analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0030DOI Listing
December 2018
1 Read

Safety and efficacy of intravenous immunoglobulin (Flebogamma 10% DIF) in patients with immune thrombocytopenic purpura.

Immunotherapy 2018 Nov 30. Epub 2018 Nov 30.

Grifols Bioscience Research Group, Grifols, Barcelona, Spain.

Aim: To evaluate the safety and efficacy of 10% intravenous immunoglobulin (IVIG; Flebogamma 10% DIF) in individuals with chronic immune thrombocytopenic purpura (ITP).

Patients & Methods: Patients aged 3-70 years, diagnosed with chronic ITP, received 1 g/kg IVIG over two consecutive days.

Results:  64 evaluable patients (51 adults, 13 children) with chronic ITP received IVIG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0165DOI Listing
November 2018
2 Reads

Immunotherapy Foreword 2018.

Authors:
Mike Gregg

Immunotherapy 2018 Nov;10(16):1339-1341

Future Science Group, Unitec House, 2 Albert Place, London N31QB, UK.

To all of our readers, the Future Medicine editorial office would like to thank you for your continued readership over 2018 and I hope you have a fantastic Christmas and New Year. I would also like to thank our esteemed editorial board, peer reviewers and contributing authors for their continued support. We very much look forward to working with you all in 2019 and seeing the journal continue to progress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0183DOI Listing
November 2018

The behavior of Italian allergists in prescribing allergen immunotherapy for house dust mites allergy.

Immunotherapy 2018 Nov;10(16):1343-1348

Istituto Giannina Gaslini, Genoa, Italy.

The meeting 'Clinical Evidence, Extracts Quality and Biotechnology Innovation in Allergen Immunotherapy' held in Trieste (Italy) on 1 October 2017 concerned the outcomes of a real-world survey conducted on a group of Italian allergists about allergen immunotherapy (AIT) for house dust mites allergy. It pointed out: allergist's confidence that AIT should be prescribed continuously; tablets seem to be well accepted by patients and effective in most subjects with a fast onset of action (3-6 months); combined score for symptom severity and medication use is universally assessed; there is disagreement about the diagnosis of house dust mites allergy, the quote of AIT prescription, the choice for AIT route of administration, assessment of serum IgE and perception of patient's adherence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0066DOI Listing
November 2018

Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells.

Immunotherapy 2018 Nov;10(16):1349-1360

Department of Ophthalmology, University of Miami, FL, USA.

Aim: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration.

Materials & Methods: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers electrostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0078
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0078DOI Listing
November 2018
2 Reads

The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.

Immunotherapy 2018 Nov;10(15):1289-1291

Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0108DOI Listing
November 2018
1 Read

Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis.

Authors:
Jing Li Jian Gu

Immunotherapy 2018 Nov;10(15):1293-1302

College of Pharmacy, Southwest Minzu University, No.16 South 4th Section, 1st Ring Road, Chengdu, Sichuan 610041, PR China.

Aim: We conducted a meta-analysis to systematically review the efficacy and safety of programmed cell death 1 (PD-1) inhibitors for advanced melanoma.

Study Design: The relevant studies of the randomized controlled trials in melanoma patients treated with PD-1 inhibitors were retrieved and the systematic evaluation was conducted. Databases were searched till June 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0116DOI Listing
November 2018
1 Read

Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis.

Immunotherapy 2018 Nov;10(15):1303-1313

Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100, Macerata, Italy.

Aim: We aimed to assess the incidence and relative risk (RR) of fatigue in cancer patients treated with anti programmed cell death-1 (PD-1) and anti programmed cell death ligand-1 (PD-L1) agents.

Patients & Methods: Eligible studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Incidence, RR and 95% CIs were calculated using random or fixed-effects models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0067DOI Listing
November 2018
2.440 Impact Factor

Factors associated with immunotherapy selection in patients with advanced melanoma.

Immunotherapy 2018 Nov 8;10(16):1361-1369. Epub 2018 Nov 8.

Center for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

Aim: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma.

Materials & Methods:  Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0150
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0150DOI Listing
November 2018
1 Read
2.440 Impact Factor

Intracellular activation of complement C3 in Paneth cells improves repair of intestinal epithelia during acute injury.

Immunotherapy 2018 Nov 1;10(15):1325-1336. Epub 2018 Nov 1.

Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, PR China.

Aim: To explore whether Paneth cells (PCs) and complement system collaborate in the repair of enteric epithelia during acute gastrointestinal injury (AGI).

Methods: Wild-type C57BL/6 mice were employed to induce AGI by performing colon ascendens stent surgery, with sham-operated as control. Exogenous C3 treatment was applied at 6-h postsurgery. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0122
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0122DOI Listing
November 2018
2 Reads
2.440 Impact Factor

Combination of PD-1 blockade and RetroNectin-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study.

Immunotherapy 2018 Nov 23;10(15):1315-1323. Epub 2018 Oct 23.

Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, PR China.

Aim: To analyze the efficacy of PD-1 blockade combined with RetroNectin-activated cytokine-induced killer (R-CIK) cells in preheavily treated advanced non-small-cell lung cancer (NSCLC).

Methods: We retrospectively analyzed patients with advanced NSCLC who received PD-1 blockade combined with R-CIK cells whose treatments failed at least two regimens.

Results: The median number of previous treatment regimens was three (range: 2-7). Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0125
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0125DOI Listing
November 2018
14 Reads
2.440 Impact Factor

Tolerability and positive efficacy results after subcutaneous immunotherapy with Parietaria judaica depot extract.

Immunotherapy 2018 Oct;10(14):1253-1263

ROXALL España, R&D Department, Zamudio 48170, Spain.

Aim: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis.

Patients & Methods: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0051DOI Listing
October 2018
1 Read

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Immunotherapy 2018 10;10(14):1229-1239

Medical Oncology Unit, University Hospital of Parma, Parma, Italy.

Aim: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population.

Methods: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017.

Results: Of 300 patients, 79 received flu vaccine. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0080
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0080DOI Listing
October 2018
1 Read
2.440 Impact Factor

Harnessing immune checkpoints for cancer therapy.

Immunotherapy 2018 Oct;10(14):1265-1284

Section of Clinical Immunology, Allergy & Rheumatology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.

Immunomodulatory antibodies that directly trigger and reawaken suppressed T-cell effector function are termed 'checkpoint inhibitors'. CTLA-4 and PD-1/PD-L1 molecules are the most studied inhibitory immune check points against cancer and because of this therapeutic property have entered the clinic for treating a variety of tumor types. The results so far demonstrate a positive impact on cancer remission. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2017-0168
Publisher Site
http://dx.doi.org/10.2217/imt-2017-0168DOI Listing
October 2018
12 Reads

Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma.

Immunotherapy 2018 Oct;10(14):1189-1192

Division of Respirology, Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada.

A 61-year-old woman with locally advanced, high-grade urothelial cell carcinoma was treated with the anti-programmed death-ligand 1 antibody atezolizumab. She initially received neoadjuvant chemotherapy and surgery that led to clinical and radiographic remission at the time of atezolizumab initiation. Within 3 months she developed new mediastinal and hilar lymphadenopathy as well as pulmonary nodules in a pattern characteristic of pulmonary sarcoidosis. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0035
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0035DOI Listing
October 2018
2 Reads

Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's disease.

Immunotherapy 2018 Oct 9;10(14):1203-1217. Epub 2018 Oct 9.

Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.

Significant unmet needs remain in patients with Crohn's disease and perianal fistulas. Mesenchymal stromal cells have potent immunomodulatory actions. The Phase II studies reported efficacy of local injection of mesenchymal stromal cells to achieve closure of fistulas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0099DOI Listing
October 2018
13 Reads

Comparative study of adjuvants for allergen-specific immunotherapy in a murine model.

Immunotherapy 2018 Oct 24;10(14):1219-1228. Epub 2018 Sep 24.

Allergy Service, Gregorio Marañón University General Hospital, Madrid, Spain.

Aim: To compare the immunological and clinical changes induced by allergen-specific immunotherapy (AIT) using different adjuvants.

Materials & Methods: Olea europaea pollen-sensitized mice were treated with olea plus aluminum hydroxide, calcium phosphate, monophosphoryl lipid A (MPL) or immunostimulatory sequences (ISS).

Results: Aluminum hydroxide seems to drive initially to a Th2-type response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0072DOI Listing
October 2018
1 Read

Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.

Immunotherapy 2018 Sep;10(13):1123-1132

Medical Oncology Unit 1, Ospedale Policlinico San Martino IST, University of Genova, Largo R. Benzi 10, 16143, Genova, Italy.

Immunotherapy is associated with different response patterns compared with chemotherapy and targeted therapy, including delayed response and stabilization after progression (pseudoprogression). According to new immuno-based response criteria, immunotherapy can be continued after radiological progression when a clinical benefit is observed. We report a case of an advanced renal cell carcinoma patient treated with nivolumab, who developed clinical benefit and delayed radiological response after initial progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0042DOI Listing
September 2018
4 Reads
2.440 Impact Factor

Gold nanoparticles-mediated photothermal therapy and immunotherapy.

Immunotherapy 2018 Sep;10(13):1175-1188

Fitzpatrick Institute for Photonics, Duke University, Durham, NC 27708, USA.

Cancer has been a significant threat to human health with more than eight million deaths each year in the world. Therefore, there is a significant need for novel technologies to effectively treat cancer and ultimately reduce cancer recurrences, treatment costs, number of radical cystectomies and mortality. A promising therapeutic platform for cancer is offered by nanoparticle-mediated therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0029DOI Listing
September 2018
1 Read

Long-term safety of α-1 antitrypsin therapy in children and adolescents with Type 1 diabetes.

Immunotherapy 2018 Sep;10(13):1137-1148

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.

Promising findings of α-1 antitrypsin (AAT) intervention in mice models of Type 1 diabetes (T1D) led researchers to investigate AAT as a therapeutic modality for β-cell preservation in recent-onset T1D patients. Our prospective, open-label Phase I/II extension study demonstrated that the administration of multiple repeated AAT infusions (up to 36) to AAT-sufficient pediatric T1D patients is safe and well-tolerated. Long-term surveillance of participants (up to 5 years) from diabetes onset revealed normal growth and pubertal progression through adolescence to attainment of full puberty and near adult height. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0047DOI Listing
September 2018

Rapid complete remission of metastatic melanoma after first-line treatment with nivolumab plus tumor-infiltrating lymphocytes.

Immunotherapy 2018 Sep;10(13):1133-1136

Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Province, China.

Melanoma is the most common type of skin cancer in both men and women in the USA. The standard treatment modality for advanced melanoma is immunotherapy, either alone or in combination. As single-agent immunotherapy is usually inadequate, combined immunotherapy might be a good choice and combined treatment modalities appropriate for melanoma need to be explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0056DOI Listing
September 2018
21 Reads
2.440 Impact Factor

Monitoring immunotherapy outcomes with circulating tumor DNA.

Immunotherapy 2018 Sep;10(12):1023-1025

Department of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0084DOI Listing
September 2018
7 Reads

Rituximab treatment for immune-complex-mediated membranoproliferative glomerulonephritis.

Immunotherapy 2018 Sep;10(12):1027-1031

Department of Nephrology, Peking University People's Hospital, Beijing,100044, China.

Immune-complex-mediated membranoproliferative glomerulonephritis (MPGN) is a new concept that refers to MPGN with immunoglobulin and C3 deposition in the kidney based on immunofluorescence examination. It is associated with pathological autoantibodies production. Rituximab, as an immunosuppressive agent, can eliminate B cells selectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0031DOI Listing
September 2018
8 Reads

The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer.

Immunotherapy 2018 Sep;10(12):1047-1052

Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Until recently, tyrosine kinase inhibitors (TKI) were the only approved drugs for the first-line treatment of metastatic renal cell carcinoma (mRCC). Emerging trials of immune checkpoint inhibitors (ICI)-based regimens have shown survival benefits over the standard TKI. These studies challenge a paradigm shift in the management of mRCC concerning the identification of the subgroup of patients that would benefit from ICI in treatment-naive mRCC, the possibility of treatment discontinuation between TKI and ICI, and the sequencing of surgery and systemic treatment. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0017
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0017DOI Listing
September 2018
6 Reads
2.440 Impact Factor

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.

Immunotherapy 2018 Sep;10(12):1041-1045

Division of Pathology & Laboratory Medicine, European Institute of Oncology, Via Ripamonti 451, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0027DOI Listing
September 2018
1 Read

The potential immune-eliciting cancer testis antigens in colorectal cancer.

Immunotherapy 2018 Sep;10(12):1093-1104

UKM Medical Molecular Biology Institute (UMBI), UKM Medical Center, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Cheras, 56000 Kuala Lumpur, Malaysia.

The identification of cancer testis antigens (CTAs) has been an important finding in the search of potential targets for cancer immunotherapy. CTA is one of the subfamilies of the large tumor-associated antigens groups. It is aberrantly expressed in various types of human tumors but is absent in normal tissues except for the testis and placenta. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0044DOI Listing
September 2018
5 Reads
2.440 Impact Factor

Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.

Immunotherapy 2018 Sep;10(12):1033-1039

Department of Rheumatology & Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Number 197 Ruijin Second Road, Shanghai 200025, China.

Administration of anti-TNFα agents has become a mainstay in the treatment of chronic inflammatory arthritis such as rheumatoid arthritis (RA) and spondyloarthritis. Adverse events, including infections and allergic reactions, have been reported. Malignancies are rare but potentially life threatening. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0022DOI Listing
September 2018
2 Reads

Early immune response regulated by a bone marrow mesenchymal stem cell model of multiple trauma in rats.

Immunotherapy 2018 Sep;10(12):1053-1064

Department of Orthopedics, PLA Army General Hospital, Beijing, 100700, China.

Aim: To explore whether transplantation of bone marrow mesenchymal stem cells (BMSCs) would reduce the immune response and protect vital organs in a rat model of femur shaft fracture combined with craniocerebral injury.

Methods: The rats were divided into an experimental group (multiple traumas and receiving BMSCs injection, n = 25), a positive control group (only received the combination injuries, n = 25) and a negative group (n = 5).

Results: Compared with the positive control group, plasma IL-6 and IL-8 were significantly lower at the early stage, and IL-10 was higher at the late period in the experimental group (p < 0. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0010
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0010DOI Listing
September 2018
4 Reads

Novel immunotherapy strategies for hepatobiliary cancers.

Immunotherapy 2018 Sep;10(12):1077-1091

Department of Medicine, Division of Hematology & Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.

Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous ongoing endeavors are investigating novel immunotherapy concepts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0024DOI Listing
September 2018
1 Read

Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Immunotherapy 2018 Oct 3;10(14):1241-1252. Epub 2018 Sep 3.

Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

Aim: To evaluate the cost-effectiveness of treatment sequences with checkpoint inhibitors in patients with BRAF wild-type melanoma.

Materials & Methods: Using a discrete event simulation model, cost and health outcomes were estimated. Pooled data from CheckMate 067/069 trials were used to calculate survival outcomes including treatment-free interval extrapolated over a patient's lifetime. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0085DOI Listing
October 2018
13 Reads

Immunotherapy in melanoma.

Immunotherapy 2018 08;10(11):987-998

UDepartment of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Immunotherapy has dramatically improved the prognosis for patients with melanoma and has become the cornerstone of treatment for those with advanced disease. The role of immunotherapy continues to expand with multiple new agents approved in the adjuvant as well as metastatic setting, as first-line therapy and beyond. We review the currently approved drugs for the treatment of melanoma, along with clinical trial data, adverse side effects, response assessment and future directions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0143DOI Listing
August 2018
12 Reads

Chimeric antigen receptor T-cell therapy hits the market.

Authors:
Michael W Boyer

Immunotherapy 2018 Aug;10(11):911-912

Associate Professor of Pediatrics & Internal Medicine, University of Utah, Division of Pediatric Hematology/Oncology/BMT, 100 N Mario Capecchi Dr, Salt Lake City, UT 84132, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0075DOI Listing

Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.

Immunotherapy 2018 Aug;10(11):913-917

Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Province, China.

Hodgkin's lymphoma is a common malignant disease, especially among children in America. Although chemotherapy and radiotherapy are mainstay treatments for Hodgkin's lymphoma, a small portion of patient experiences relapsed or refractory diseases. Nivolumab provides an option for patients who experience relapsed or refractory disease, but adverse effects may occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0025DOI Listing
August 2018
2 Reads
2.440 Impact Factor

An overview of cancer immunotherapeutic strategies.

Immunotherapy 2018 Aug;10(11):999-1010

Genome Centre for Molecular Based Diagnostics & Research, Cl-25 Block B Al-Sudais Plaza, Abdalian Cooperative Society, Lahore, Pakistan.

Artificially boosting body's immune response is one of the most exciting, effective and promising advancements in the treatment of cancers. Cancer immunotherapeutics consist of variety of treatment approaches such as cytokine therapy, adoptive T-cell transfer therapy, and antibodies that stimulate innate and adoptive immune responses. In addition to this, development of HPV vaccine has paved way toward the development of other cancer vaccines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0002DOI Listing
August 2018
8 Reads
2.440 Impact Factor

Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.

Immunotherapy 2018 Aug;10(11):935-949

The Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu, China.

Tumor immunotherapy has shown great progress for the treatment of cancer; however, both endogenous and exogenous T cells are inhibited by the immunosuppressive tumor microenvironment. Tumor-associated macrophages (TAMs) in the microenvironment play pivotal and complex roles in tumor development and progression. Macrophages are categorized as M1 and M2 types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0012DOI Listing
August 2018
8 Reads

Combination therapy of hepatocellular carcinoma by DNA shuffling-based VEGF vaccine and doxorubicin.

Immunotherapy 2018 Aug 17;10(11):951-969. Epub 2018 Aug 17.

College of Life Science & Technology, Huazhong Agricultural University, Wuhan 430070, HuBei Province, P.R. China.

Antiangiogenic therapy can enhance the efficacy of chemotherapy against solid tumors. This study was to determine whether TT46, a potential VEGF vaccine from DNA shuffling with a helper T-cell epitope of tetanus toxin B subunit, could enhance the efficacy of doxorubicin to combat hepatocellular carcinoma (HCC). Compared with monotherapy, the combination with TT46 vaccination and doxorubicin could significantly reduce microvessel counts and inhibit tumor angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0194DOI Listing
August 2018
4 Reads

Subcutaneous belimumab in the treatment of systemic lupus erythematosus.

Immunotherapy 2018 Sep 14;10(13):1163-1173. Epub 2018 Aug 14.

Department of Medicine, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto Lupus Clinic, Toronto, Ontario, Canada.

Systemic lupus erythematosus is a chronic autoimmune disease with various clinical manifestations, organ involvement and laboratory findings. The disease can involve any organ including skin, joints, kidneys, central and peripheral nervous system, cardiovascular system and more. Currently, the cornerstone of treatment includes antimalarial and immunosuppressive medications and glucocorticosteroids. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0061
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0061DOI Listing
September 2018
7 Reads
2.440 Impact Factor

Efficacy and tolerability of a house dust mite allergoid in allergic bronchial asthma: a randomized dose-ranging trial.

Immunotherapy 2018 Sep 9;10(13):1149-1161. Epub 2018 Aug 9.

Barlicki University Hospital, Medical University, Lodz, Poland.

Aim: This multicenter randomized placebo-controlled double-blind clinical trial investigated which maintenance dose shows the optimal benefit-risk ratio for subcutaneous immunotherapy with a Dermatophagoides pteronyssinus allergoid preparation.

Objective: To evaluate four maintenance doses of the allergoid preparation versus placebo.

Methods: The late-phase reaction of the intracutaneous test was chosen as efficacy parameter and minimal dose of fluticasone required for asthma control. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0087
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0087DOI Listing
September 2018
5 Reads

Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.

Immunotherapy 2018 Oct 8;10(14):1193-1202. Epub 2018 Aug 8.

Division of Pediatric Allergy and Immunology, Department of Pediatrics, UCLA School of Medicine, Los Angeles, CA 90095, USA.

Aim: To assess the safety and efficacy of an intravenous immunoglobulin (IVIG) 10% preparation (Panzyga; Octapharma AG, Lachen, Switzerland) in predominantly antibody-deficient children with primary immunodeficiency disease.

Methods: Data from two prospective, open-label and noncontrolled multicenter Phase III studies of IVIG 10% that included 25 patients <16 years of age were analyzed for efficacy, pharmacokinetics and safety.

Results: The rate of serious bacterial infections was 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0074DOI Listing
October 2018
2 Reads

Tildrakizumab for the treatment of psoriasis.

Immunotherapy 2018 Sep 7;10(13):1105-1122. Epub 2018 Aug 7.

Juvenis Medical Center, 1010 Vienna, Austria.

Psoriasis is a chronic skin disorder driven by IL-23 and the downstream T-helper cell 17 (Th17) pathway. Tildrakizumab is a humanized monoclonal antibody selectively targeting the p19 subunit of IL-23, a key cytokine for Th17 cells. Here, we provide an overview of IL-23 in the context of psoriasis pathogenesis and review the results of the Phase I, II and III clinical trials for tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis in order to assess its efficacy, safety and clinical usefulness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0028DOI Listing
September 2018

Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals.

Immunotherapy 2018 Aug;10(10):871-885

Laboratorio de Investigacao em Dermatologia e Imunodeficiencias, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. 05403-903, Brazil.

Aims: A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine.

Patients & Methods: Monocytes obtained from 17 HIV-infected individuals were differentiated into MDDCs and, after loading with autologous HIV, the cells were characterized concerning surface molecule expression, migratory and phagocytosis capacity, cytokine production and the induction of an effective cell-mediated immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0165DOI Listing
August 2018
5 Reads

Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.

Immunotherapy 2018 Aug;10(10):851-0

Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.

Given the unprecedentedly rapid progression of clinical immuno-oncology, evaluation of currently ongoing and upcoming clinical trials is essential to address potential deficiencies for future trial design. This observational study examined trends in the current landscape of clinical trials investigating immunotherapy with radiotherapy (iRT). The National Institute of Health's clinicaltrials. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0019
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0019DOI Listing
August 2018
3 Reads

Where do immune checkpoint inhibitors stand in the management of thymic epithelial tumors?

Immunotherapy 2018 Aug;10(10):823-826

Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0069DOI Listing

Dual role of macrophage in tumor immunity.

Immunotherapy 2018 Aug;10(10):899-909

Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Macrophages are significant in immune responses, assuming a defensive role. In contrast, macrophages often cause undesirable changes. These reactions are processes by which macrophages express different functional programs in response to microenvironmental signals, defined as M1/M2 polarization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0006DOI Listing

Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report.

Immunotherapy 2018 08;10(10):831-835

Department of Medical Oncology, Centre Leon Berard, Claude Bernard University, Lyon, France.

Primary malignant melanoma of the esophagus is rare, accounting for less than 0.1-0.2% of all esophageal malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0011DOI Listing
August 2018
8 Reads
2.440 Impact Factor

Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access.

Immunotherapy 2018 Aug;10(10):887-897

Research Centre/Department of Medical Oncology, Oncology and Hematology Nucleus of Ceará (NOHC), Fortaleza, CE, Brazil.

Aim: Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation.

Methods: The number of patients with non-small-cell lung cancer eligible for immunotherapy was estimated using local epidemiology data. We extracted survival data from RCTs to estimate the life-years saved in a 5-year time horizon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0183DOI Listing

Cytokine-induced killer cell therapy as a promising adjunctive immunotherapy for multidrug-resistant pulmonary TB: a case report.

Immunotherapy 2018 Aug;10(10):827-830

Department of Clinical Laboratory, The Fifth People's Hospital of Suzhou, Suzhou, China.

In this report, we identified a multidrug-resistant tuberculosis (MDR-TB) patient who remained acid-fast bacilli culture positive despite aggressive WHO-directed therapy. Between July 2014 and February 2015, she received eight courses of cytokine-induced killer (CIK) cell-based adoptive cellular immunotherapy in combination to the second-line anti-TB treatment. This case achieved culture conversion, and experienced no relapse during 2-year follow-up under the treatment with CIK cell-based adoptive cellular immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0192DOI Listing
August 2018
2.440 Impact Factor

Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.

Immunotherapy 2018 Aug 3;10(11):1011-1021. Epub 2018 Aug 3.

Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.

Analytical similarity is the foundation of the totality-of-evidence-based approach for demonstrating that a proposed biosimilar is highly similar to a reference product. This review uses analytical similarity assessment of ABP 501, the first approved adalimumab biosimilar, as a case study to highlight considerations necessary to demonstrate analytical similarity. Similarity assessments start with risk-ranking the critical quality attributes based on scientific understanding of how they impact safety, efficacy, immunogenicity and/or pharmacokinetics/pharmacodynamics. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2018-0040
Publisher Site
http://dx.doi.org/10.2217/imt-2018-0040DOI Listing
August 2018
9 Reads